Dr Reddys gets approval from DCGI for emergency use of Sputnik V

Shruti Dahiwal
/ Categories: Trending
Dr Reddys gets approval from DCGI for emergency use of Sputnik V

Dr Reddy’s Laboratories Ltd, an integrated pharmaceutical company, announced this morning that Drug Controller General of India (DCGI) has granted it the permission to import Sputnik vaccine into the country for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials Rules, 2019 under Drugs & Cosmetics Act.  

Last year, in the month of September, the company had collaborated with Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and distribute the vaccine in India. In addition to the trials conducted by RDIF in Russia, Dr Reddy’s had also carried out the Phase 2 and 3 clinical trials of the vaccine.  

The vaccine, Sputnik V has authorisation in 60 countries around the world and ranks second among Coronavirus vaccines globally in terms of the number of approvals issued by the government regulators. As per the medical journal Lancet, the vaccine has an efficacy rate of 91.6 per cent.  

“We are very pleased to obtain the emergency use authorisation for Sputnik V in India. With the rising cases in India, vaccination is the most effective tool in our battle against COVID-19. This will enable us to contribute to our nation’s effort of vaccinating a significant proportion of our population,” says GV Prasad, Co-Chairman and MD of Dr Reddy’s Laboratories.  

At 12.50 pm, the share price of Dr Reddy’s Laboratories Ltd was trading at Rs 4,823.60, which was a fall of 3.32 per cent over its previous closing price of Rs 4,989.20 on BSE. 

Rate this article:
4.5

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Interviews28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR